Holen Sie sich die Stockscreener-App
6.52
2.68%
0.17
Handel nachbörslich:
6.65
0.13
+1.99%
Schlusskurs vom Vortag:
$6.35
Offen:
$6.39
24-Stunden-Volumen:
49,476
Relative Volume:
0.37
Marktkapitalisierung:
$165.98M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-22.38M
KGV:
-4.6241
EPS:
-1.41
Netto-Cashflow:
$-15.54M
1W Leistung:
-0.15%
1M Leistung:
-10.56%
6M Leistung:
+2.84%
1J Leistung:
-1.36%
1-Tages-Spanne:
$6.36
$6.59
1-Wochen-Bereich:
$6.32
$6.745
52-Wochen-Spanne:
$4.44
$11.80
Nuvectis Pharma Inc Stock (NVCT) Company Profile
Firmenname
Nuvectis Pharma Inc
Sektor
Branche
Telefon
360-837-7232
Adresse
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Vergleichen Sie NVCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
6.52 | 162.41M | 0 | -22.38M | -15.54M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-02 | Eingeleitet | Maxim Group | Buy |
| 2025-03-17 | Eingeleitet | Laidlaw | Buy |
| 2022-07-13 | Eingeleitet | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc Aktie (NVCT) Neueste Nachrichten
How institutional ownership impacts Nuvectis Pharma Inc. stock2025 Risk Factors & Reliable Breakout Forecasts - Newser
Has Nuvectis Pharma Inc. formed a bullish divergence2025 Market Outlook & Verified Momentum Stock Alerts - Newser
Custom watchlist performance reports with Nuvectis Pharma Inc.July 2025 Highlights & Free Long-Term Investment Growth Plans - Newser
How to escape a deep drawdown in Nuvectis Pharma Inc.Recession Risk & Trade Opportunity Analysis - Newser
Best data tools to analyze Nuvectis Pharma Inc. stockWeekly Earnings Recap & Safe Entry Momentum Tips - Newser
What recovery options are there for Nuvectis Pharma Inc.CPI Data & Comprehensive Market Scan Insights - Newser
Will breakout in Nuvectis Pharma Inc. lead to full recoveryJuly 2025 Trade Ideas & Community Verified Trade Alerts - Newser
Applying sector rotation models to Nuvectis Pharma Inc.July 2025 Trends & High Conviction Trade Alerts - Newser
Earnings visualization tools for Nuvectis Pharma Inc.2025 Trade Ideas & Fast Entry Momentum Trade Alerts - Newser
Automated trading signals detected on Nuvectis Pharma Inc.Weekly Stock Recap & Scalable Portfolio Growth Ideas - Newser
How high can Nuvectis Pharma Inc. stock goGlobal Markets & AI Enhanced Trading Alerts - Newser
Nuvectis Pharma Inc. recovery potential after sell off2025 Key Highlights & High Accuracy Buy Signal Tips - Newser
Nuvectis Pharma Inc. stock trend outlook and recovery pathJuly 2025 Levels & Proven Capital Preservation Tips - Newser
Evaluating Nuvectis Pharma Inc. with trendline analysisWeekly Trend Summary & Community Trade Idea Sharing Platform - Newser
What is Nuvectis Pharma Inc. s 5 year growth outlookWeekly Profit Analysis & Consistent Return Strategy Ideas - khodrobank.com
Volume spikes in Nuvectis Pharma Inc. stock – what they mean2025 Valuation Update & Fast Exit Strategy with Risk Control - Newser
Applying Elliott Wave Theory to Nuvectis Pharma Inc.Chart Signals & High Conviction Buy Zone Picks - Newser
Is Nuvectis Pharma Inc. stock bottoming outMarket Weekly Review & Daily Stock Trend Watchlist - Newser
Is Nuvectis Pharma Inc. trending in predictive chart models2025 Macro Impact & Technical Confirmation Alerts - Newser
Can momentum traders help lift Nuvectis Pharma Inc.2025 Institutional Moves & Detailed Earnings Play Strategies - Newser
What Fibonacci levels say about Nuvectis Pharma Inc. reboundEarnings Risk Report & Fast Gain Stock Tips - Newser
Candlestick signals on Nuvectis Pharma Inc. stock todayWeekly Stock Analysis & Weekly Top Gainers Trade List - Newser
Is Nuvectis Pharma Inc. stock ready for a breakoutJuly 2025 Earnings & Fast Entry and Exit Trade Plans - Newser
Nuvectis Pharma Inc. stock chart pattern explainedPortfolio Return Report & Accurate Buy Signal Notifications - Newser
A | What is Nuvectis Pharma, Inc.'s 5-year growth outlookQuarterly Portfolio Review & AI Optimized Trading Strategy Guides - khodrobank.com
Nuvectis pharma investor acquires $1.2 million in stock - MSN
Earnings visualization tools for Nuvectis Pharma IncFed Meeting & Fast Gain Stock Trading Tips - Newser
Nuvectis Pharma Inc. stock prediction for this weekQuarterly Growth Report & Technical Buy Zone Confirmations - Newser
Nuvectis Pharma Inc. Recovery Likely Here’s What Data Shows getLinesFromResByArray error: size == 0 - kangso.co.kr
What makes Nuvectis Pharma Inc. stock price move sharplyTrade Exit Report & Safe Entry Zone Identification - Newser
Does Nuvectis Pharma Inc. fit your quant trading modelJuly 2025 Trade Ideas & Weekly High Conviction Trade Ideas - Newser
Finanzdaten der Nuvectis Pharma Inc-Aktie (NVCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Nuvectis Pharma Inc-Aktie (NVCT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mosseri Marlio Charles | 10% Owner |
Jun 18 '25 |
Buy |
8.05 |
28,043 |
225,746 |
2,976,203 |
| Mosseri Marlio Charles | 10% Owner |
Jun 17 '25 |
Buy |
8.11 |
5,399 |
43,786 |
2,948,160 |
| Mosseri Marlio Charles | 10% Owner |
May 12 '25 |
Buy |
8.11 |
21,167 |
171,664 |
2,942,761 |
| Mosseri Marlio Charles | 10% Owner |
May 06 '25 |
Buy |
8.59 |
12,444 |
106,955 |
2,896,565 |
| Mosseri Marlio Charles | 10% Owner |
May 07 '25 |
Buy |
8.59 |
12,317 |
105,770 |
2,908,882 |
| Mosseri Marlio Charles | 10% Owner |
May 08 '25 |
Buy |
8.65 |
2,650 |
22,922 |
2,911,532 |
| Mosseri Marlio Charles | 10% Owner |
Feb 07 '25 |
Buy |
5.00 |
240,000 |
1,200,000 |
2,884,121 |
| BENTSUR RON | Chairman & CEO |
Dec 24 '24 |
Buy |
4.65 |
4,500 |
20,925 |
3,270,924 |
| Mosseri Marlio Charles | 10% Owner |
Dec 13 '24 |
Buy |
4.70 |
17,000 |
79,900 |
2,612,000 |
| Poradosu Enrique | Chief Science & Business Off |
Nov 19 '24 |
Buy |
4.99 |
2,000 |
9,980 |
1,506,319 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):